EB-1010
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for EB-1010, covering 2015-12-04 to 2015-12-04. Get the full timeline:
Most recent: Clinical Trial Update: A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) [Phase 2, Phase 3]